September 06, 2016
Authored and Edited by Hala S. Mourad; Cory C. Bell
In Praxair Distribution, Inc. v. INO Therapeutics, LLC., IPR2016-00781, Paper 10 (Aug. 25, 2016), the Board denied Praxair’s inter partes review petition based on both estoppel under 35 U.S.C. § 315(e)(1) and the PTAB’s discretion under § 325(d).
The petition challenged the same claims of U.S. Patent No. 8,846,112 as a prior petition filed by Praxair, but based on two new textbook references. Praxair asserted that it did not cite the new references in the earlier IPR because it did not discover them before filing. As evidence, Praxair provided a list of exemplary search results from Cardinal Intellectual Property, Inc.
The Board based its estoppel determination on whether the new references were “prior art which a skilled searcher conducting a diligent search reasonably could have been expected to discover.” The Board found the single search report insufficient to show that a reasonable search was conducted, highlighting the following facts:
The Board also exercised its discretion to deny Praxair’s petition under § 325(d). They reached this conclusion not only because “the same or substantially the same arguments” were previously presented but also because Praxair “should have been aware of the newly-cited . . . references when it filed the earlier Petition.”
America Invents Act (AIA), estoppel, Patent Trial and Appeal Board (PTAB), rules and rules of practice
Copyright © 2016 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information.
Seminar
U.S. Patent Litigation 2026: Key Developments, Strategic Trends, and Winning Before Trial
November 6, 2026
Taipei
Seminar
The Augmented Practice 2026: Balancing AI Opportunity, Governance, and Risk
November 5, 2026
San Francisco
Hybrid Conference
2026 Patent Law Institute: Critical Issues & Best Practices – New York
October 29, 2026
New York
Hybrid Conference
Intellectual Property Law Institute 2026 – California
October 19-20, 2026
San Francisco
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.